Department of Orthopaedic Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
Department of Radiology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan.
Spine J. 2023 Oct;23(10):1540-1548. doi: 10.1016/j.spinee.2023.06.389. Epub 2023 Jun 21.
After palliative radiotherapy of spinal bone metastases, re-ossification is sometimes observed in bone with osteolytic changes. However, it remains unknown whether the re-ossification that is observed after radiotherapy is associated with preservation of vertebral body height.
To investigate whether re-ossification observed after palliative radiotherapy can contribute to the preservation of vertebral body height.
This is a retrospective observational study.
We investigated 111 vertebral bodies in 54 patients that underwent palliative radiotherapy at a single center for painful osteolytic/mixed metastatic spinal tumors in solid tumors between 2016 and 2020.
The outcome measures were the presence of re-ossification and vertebral body height reduction on the CT image.
Re-ossification was evaluated according to the MD Anderson response classification criteria, and sagittal CT images were used to evaluate vertebral body height. A vertebral body ID was assigned to the irradiated vertebral body, and continuous CT images obtained for each vertebral body ID were evaluated. The median number of evaluation periods for each vertebral body was 4, and the total number of periods was 463. Logistic regression analysis was performed to investigate factors related to the occurrence of vertebral body height reduction before the subsequent CT. As a subanalysis, factors related to re-ossification were investigated.
The following primary cancer types were observed: lung cancer, 41 vertebral bodies; breast cancer, 19; renal cell cancer, 15; other, 36. A total of 62.2% showed re-ossification. The median time to confirmation of re-ossification by CT was 2 months. Factors significantly associated with vertebral body height reduction were presence of vertebral body height reduction before radiotherapy (odds ratio [OR] 6.8, 95% confidence interval [CI] 2.0-63, p=.01) and no re-ossification (OR 137, 95% CI 22-3469, p<.01). Factors associated with re-ossification were the type of cancer and total radiation dose. Those with lung cancer and those with a total radiation dose of 20 Gy or less were more prone to re-ossification.
Re-ossification was observed in 62.2% of vertebral bodies after palliative radiotherapy for painful osteolytic/mixed metastatic spinal tumors. The re-ossification group demonstrated significantly less vertebral body height reduction when compared with the non-re-ossification group. The presence of re-ossification may potentially serve an important role in maintaining vertebral body height.
在脊柱骨转移瘤的姑息性放疗后,骨的溶骨性变化有时会出现再矿化。然而,目前尚不清楚放疗后观察到的再矿化是否与椎体高度的保持有关。
研究姑息性放疗后观察到的再矿化是否有助于保持椎体高度。
这是一项回顾性观察研究。
我们调查了 2016 年至 2020 年间在一家中心接受姑息性放疗治疗疼痛性溶骨性/混合性转移性脊柱肿瘤的 54 例患者的 111 个椎体。
结果测量包括 CT 图像上再矿化和椎体高度降低的存在。
根据 MD Anderson 反应分类标准评估再矿化,使用矢状 CT 图像评估椎体高度。为照射椎体分配椎体 ID,并评估每个椎体 ID 的连续 CT 图像。每个椎体的中位数评估期数为 4 次,总评估期数为 463 次。对与后续 CT 前椎体高度降低相关的因素进行逻辑回归分析。作为亚分析,研究了与再矿化相关的因素。
观察到的主要癌症类型为:肺癌,41 个椎体;乳腺癌,19 个;肾细胞癌,15 个;其他,36 个。共有 62.2%的患者出现再矿化。CT 确认再矿化的中位时间为 2 个月。与椎体高度降低相关的因素包括放疗前椎体高度降低(优势比[OR]6.8,95%置信区间[CI]2.0-63,p=.01)和无再矿化(OR 137,95%CI 22-3469,p<.01)。与再矿化相关的因素是癌症类型和总辐射剂量。肺癌患者和总辐射剂量为 20 Gy 或更少的患者更容易发生再矿化。
在姑息性放疗治疗疼痛性溶骨性/混合性转移性脊柱肿瘤后,62.2%的椎体出现再矿化。与非再矿化组相比,再矿化组的椎体高度降低明显较少。再矿化的存在可能在保持椎体高度方面发挥重要作用。